Experience
Senju Pharmaceutical Co.; Bausch + Lomb
Lupin Ltd.
Secured a permanent injunction against generic defendants on behalf of Senju and Bausch + Lomb in Hatch-Waxman patent infringement litigation concerning multiple ANDAs for generic versions of Prolensa®.
Senju Pharmaceutical Co.; Bausch + Lomb v. Lupin Ltd., 1:14-cv-00667, -04149; 1:15-cv-00335; 1:16-cv-01097, D.N.J., Judges Goodman, Shipp, Simandle, Williams
Hartig Drug Co. Inc. v. Senju Pharmaceutical Co. Ltd.
Senju Pharmaceuticals Co. Ltd.
Otsuka Pharmaceutical Co., Ltd. v. Apotex Corp.
Otsuka Pharmaceutical Co., Ltd.
Senju Pharmaceutical Co., Ltd. v. Apotex Inc.
Senju Pharmaceutical Co., Ltd.; Bausch + Lomb Inc.
InnoPharma Licensing, Inc.; Lupin Ltd.; and Metrics, Inc. v. Senju Pharmaceuticals Co.
Bausch Health Companies
Medicis Pharmaceutical Corp. v. Apotex, Inc.
Medicis Pharmaceutical Corp.
Otsuka Pharmaceutical Co., Ltd. v. Teva Pharmaceuticals USA, Inc.
Otsuka Pharmaceutical Co.
Housey Pharmaceuticals, Inc. v. Otsuka Pharmaceutical Co. Ltd.
Otsuka Pharmaceutical Co. Ltd.
Apotex Inc. v. Senju Pharmaceutical
Senju Pharmaceuticals Co. Ltd.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.